BiogenBIIB

• Phase 1BIIB144 건강한 성인 대상 안전성 1상 임상시작 전A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo
  73%
• Phase ?다발성경화증 환자의 나탈리주맙 피하주사 항체 발생 분석진행 중A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
  59%
• Phase 3리티필리맙(BIIB059) 피부 루푸스 장기 연장 임상진행 중A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
  87%
• Phase 2신장이식 후 미세혈관 염증 대상 펠자르타맙 임상모집 중A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
  41%
• Phase 3BIIB059 전신홍반루푸스 장기 안전성 임상진행 중An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
  62%
• Phase 3IgA 신증 성인 환자 대상 펠자르타맙 유효성 임상모집 중A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
  45%
• Phase 3원발성 막성 신증 대상 Felzartamab 효능 임상모집 중A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
  56%
• Phase 3신장이식 거부반응 치료제 펠자르타맙 장기 임상시작 전A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
  68%
• Phase 2BIIB059 피부 루푸스 치료 효과 및 안전성 임상모집 중A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
  59%
• Phase 3펠자타맙 신장이식 항체매개 거부반응 치료 임상모집 중A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
  56%
• Phase 3Salanersen(BIIB115) 척수성 근위축증 유아 대상 임상시작 전A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
  40%
• Phase 3척수성 근위축증(SMA) 대상 BIIB115 운동기능 개선 임상시작 전A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
  33%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.